The FDA published a Federal Register notice today, April 16, 2026, officially opening a public comment docket on BPC-157, TB-500, KPV, and MOTS-c. If you want the advisory committee voting on July 23 to hear from you, your comment must be in by July 9, 2026.
This is the single most consequential regulatory window for the peptide community in the last decade. Once the vote happens, the 503A Bulks List gets set for years.
What the FDA Just Did
On April 16, 2026, the FDA published the official Federal Register notice (docket FDA-2025-N-6895) establishing the public docket and requesting comments on bulk drug substances nominated for inclusion on the 503A Bulk Drug Substances List. This is the procedural step that opens the meeting to public input.
Four peptides are on the agenda for July 23:
- BPC-157 (free base and acetate) — nominated for ulcerative colitis
- KPV (free base and acetate) — nominated for wound healing and inflammatory conditions
- TB-500 (free base and acetate) — nominated for wound healing
- MOTS-c (free base and acetate) — nominated for obesity
If the Pharmacy Compounding Advisory Committee votes to add these to the 503A Bulks List, 503A compounding pharmacies will be allowed to prepare them for patients under a physician prescription. If the committee votes against, they stay off the list and the only legal path to these peptides is research use from vendors.
Context from this week: the Washington Post reported on April 15 that the FDA is openly weighing whether to lift restrictions on MAHA-favored peptides, and STAT News reports the advisory panel is expected to support broader access. Hims & Hers stock jumped on the news. The political wind is behind reclassification — but advisory committee votes are not foregone conclusions. Public comments influence the record.
Key Dates
| Date | What Happens |
|---|---|
| April 16, 2026 | Federal Register notice published, docket opens |
| July 9, 2026 | Deadline for comments to reach the committee |
| July 22, 2026 | Final deadline (comments after this date only go to FDA staff) |
| July 23-24, 2026 | Advisory committee meets at FDA White Oak Campus |
| Later 2026 | FDA issues final guidance |
How to Submit a Public Comment (Step by Step)
The process takes about 10 minutes. You do not need a lawyer, a medical degree, or any credentials.
1. Go to regulations.gov. Search for docket number FDA-2025-N-6895. Or go directly to the Federal Register notice published April 16, 2026, and click the "Submit a Comment" button.
2. Identify the specific peptide(s) you want to address. One comment per peptide is cleaner than a blanket comment covering all four. If you have experience with BPC-157 for healing, focus the comment on BPC-157. If you care about all four, consider filing four separate comments.
3. Write the comment. Keep it under one page. The committee reads hundreds of these. Structure that works:
- Who you are. One line. Patient, practitioner, researcher, nurse, veteran, athlete.
- Your specific experience with the peptide. What condition, what dose, what outcome, how long.
- Why the 503A pathway matters to you. Cost of ineligibility. Safety implications of the research-only market.
- Ask. Explicitly support inclusion on the 503A Bulks List for the nominated use.
4. Attach supporting documents if relevant. Published studies, lab results, physician letters. PDFs accepted.
5. Submit. You will receive a confirmation with a tracking number.
What Makes a Comment Persuasive
Individual stories beat form letters every time. The committee is looking for evidence that a compound has a real therapeutic use case that can't be met by commercially available drugs. Details that help:
- Specific conditions (ulcerative colitis flare, rotator cuff tear, chronic tendinopathy, idiopathic inflammation)
- Specific outcomes (resolution of symptoms, return to work, avoidance of surgery)
- Specific safety history (no adverse events over X months, comparison to prior failed treatments)
- Specific reason the commercial alternative is inadequate (biologics failed, cost prohibitive, side-effect profile)
Details that don't help:
- "I love peptides, keep them legal" — no therapeutic evidence
- "The FDA has no right to ban" — doesn't address the committee's legal question
- Copy-paste form letters — flagged and grouped, counted as one
What This Means for You Right Now
Three practical implications depending on where you sit:
If you currently use BPC-157, TB-500, KPV, or MOTS-c and want legal access through a 503A compounding pharmacy going forward: File a comment by July 9. Your personal case is the exact evidence the committee needs to justify 503A inclusion.
If you're a practitioner who prescribes these peptides: File a comment with your NPI/credentials and specific patient population data (de-identified). Practitioner voices carry procedural weight.
If you're currently sourcing these peptides and want to continue after the ruling: Regardless of how the July vote goes, research-use vendors will continue operating. If you want to stockpile at current prices before any supply disruption, check our /best/ pages for in-stock inventory with verified COAs.
Top BPC-157 Vendors
Ranked by price, COA availability, and reputation
